![These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019 These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=byl719-05.jpg&id=721840)
These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019
FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer | Novartis
![Breast cancer precision medicine! Novartis PI3K inhibitor Piqray received EU approval: the first PIK3CA mutation HR+/HER2- breast cancer therapy! - Knowledge - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd Breast cancer precision medicine! Novartis PI3K inhibitor Piqray received EU approval: the first PIK3CA mutation HR+/HER2- breast cancer therapy! - Knowledge - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd](https://www.hsppharma.com/Content/uploads/2020524038/20200806093612ae34e95bd63246fda578934397f34940.png)